Erectile Dysfunction (ED) Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 163 SKU: IRTNTR72378

Erectile Dysfunction (ED) Drugs Market 2024-2028

The global erectile dysfunction (ED) drugs market size is estimated to grow by USD 1.44 billion at a CAGR of 6.67% between 2023 and 2028. 

The awareness of erectile dysfunction is growing across the world as it is an underdiagnosed and undertreated disorder. To overcome the lack of awareness regarding the conditions that lead to ED, several organizations, healthcare agencies, and government bodies are focusing on improving the quality of life of the patients. Furthermore, there are several erectile dysfunction support groups, under which patients are provided with information on personal experiences, the side effects of drugs, the dosage forms to be taken, information on the mechanism of action, and the half-life of the drugs used for the treatment of ED. Hence, the rising awareness of ED will fuel the growth of the market market during the forecast period.

Technavio has segmented the market into End-user, Product, and Geography

  • The end-user segment includes hospital pharmacy, retail pharmacy, and online pharmacy
  • The product segment includes oral drugs, topical drugs, and others
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Erectile Dysfunction (ED) Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

Erectile Dysfunction (ED) Drugs Market Segmentation by End-user, Product, and Geography Analysis

End-user Analysis 

Hospital Pharmacy 

The market share growth by the hospital pharmacy segment will be significant during the forecast period. The hospital comprises pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies and used for the treatment of either outpatients or inpatients. The ED drugs are found in hospital pharmacies for ED treatments. Hospital pharmacies are the preferred end-user for ED drugs. They may provide advice on drug dosages, interactions, and potential side effects, as well as monitor patient adherence to medication regimens. This can help to enhance patient outcomes.

Get a glance at the market contribution of various segments Download PDF Sample

The hospital pharmacy segment was valued at USD 1.54 billion in 2018. Moreover, hospital pharmacies also play a key role in clinical trials. Hospital pharmacies are often involved in the preparation and dispensing of medications used in these trials. By participating in clinical trials, hospital pharmacies contribute to the development of new drugs. All such factors make hospital pharmacy a critical channel that drives the segment growth; this, in turn, is expected to drive the growth of the erectile dysfunction (ED) Drugs market during the forecast period.

Product Segment Analysis

Oral drugs

Oral drugs were the first to be developed for the treatment of ED. These drugs have been dominating the market for a long time due to the ease of administration or self-administration. Moreover, the OTC availability of these drugs is a major factor that contributes to their large market share. Furthermore, the patent expiration of these drugs is paving the way for genericization, which is responsible for the declining growth of this segment. The patents for drugs such as VIAGRA and CIALIS have already expired in major economies such as Europe and the US. Hence, such factors are expected to impede the growth of the oral drugs segment of the erectile dysfunction drugs market during the forecast period.

Topical drugs

Topical drugs for the treatment of ED have demonstrated significant improvements in penile erection. The topical drugs for the treatment of ED are available in the form of gels and creams. Vitaros (alprostadil) is one of the topical cream formulations developed by Apricus Biosciences. This drug was withdrawn by the company because of the inconvenience of use and poor response. Similar drugs are available in different regions across the world. The year-over-year growth of this segment is expected to increase. Thus, such factors are expected to drive the growth of the tropical drugs segment of the erectile dysfunction drugs market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The ED drugs market in North America is led by the US. The growth of the market is driven by the increasing prevalence of chronic diseases. In addition, menopausal symptoms, such as vulvovaginal and clitoral atrophic change, vaginal thinning, and decreased elasticity, further result in dryness and the onset of dyspareunia.

Furthermore, key drugs for ED, including VIAGRA and CIALIS, have faced patent expiration in countries such as the US and Canada. In addition, the US is a developed country, and the economic status of the population is favorable. Thus, they opt for such expensive alternative modes of treatment. The genericization and the increased adoption of alternative treatments are leading to the decelerating growth of the erectile dysfunction drugs market in North America during the forecast period.

COVID Recovery Analysis

The outbreak of COVID-19 in 2020 had a negative impact on the ED drugs market in North America. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and travel restrictions, which led to the resumption of supply chain activities. Consequently, the demand for ED drugs rebounded with access to hospitals and clinics being restored. Moreover, the region is witnessing growing approval of new drugs that treat ED. Thus, owing to these factors, the regional erectile dysfunction drugs market is expected to witness significant growth during the forecast period.

Buy Full Report Now

Key Erectile Dysfunction (ED) Drugs Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Endo International Plc: The company offers erectile dysfunction drug namely edex.

  • Bayer AG
  • Cipla Ltd.
  • Dong A Socio Holdings Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • Futura Medical plc
  • Innovcare Lifesciences Pvt. Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • SK Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TTK Healthcare Ltd.
  • Viatris Inc.
  • VIVUS LLC

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Erectile Dysfunction (ED) Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Erectile Dysfunction (ED) Drugs Market Drivers

Rising demand for ED drugs is the key factor driving market growth. With the rising health consciousness across the world, there has been a significant increase in healthcare spending for sexual wellness. As a result of this, there has been a surge in the demand for drugs for the treatment of disorders such as ED. This demand is arising not only due to the OTC availability of drugs but also because of the increase in the number of prescriptions for ED. Owing to the availability of treatment guidelines, physicians are using drug therapies for the treatment of ED.

Furthermore, the therapeutic benefits of drugs, such as a longer half-life in the body and the ease of administration even via the sublingual route, are expected to drive the adoption of ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are also expected to drive the growth of the global erectile dysfunction (ED) market during the forecast period.

Significant Erectile Dysfunction (ED) Drugs Market Trends

The presence of novel drug formulations in late stages of development is the primary trend shaping market growth. The market is dominated by the oral formulations of the drugs used for the treatment of ED. However, in the next five years, several novel formulations of ED drugs, such as topical gels, injectables, and suppositories, are expected to emerge in the market. These novel formulations will attract a large number of patients owing to their therapeutic benefits. They are also expected to widen the scope of treatment for ED.

Moreover, for instance, the MonoSol Rx tadalafil oral soluble film by Adamis Pharmaceuticals is currently in the pre-registration stage of evaluation for the treatment of ED. The drug is the first sublingual formulation and is the first film alternative to the oral tablets available for the treatment of ED. Thus, such developments are expected to propel the growth of the global erectile dysfunction (ED) market in focus during the forecast period.

Major Erectile Dysfunction (ED) Drugs Market Challenges

Availability of generics is a challenge that affects market growth. The entry of generic drugs has resulted in hampering the revenue growth of the global ED drugs market. For example, the generic version of VIAGRA, such as sildenafil citrate, is approved by the FDA. Other generic drugs for erectile dysfunction include Avanafil, Tadalafil, and Vardenafil, which is also commercially available. The sales of Viagra have declined in recent years.

Moreover, the decline in sales of Viagra led to a decline in the market share of Pfizer, which impacted the revenue generation for the company. Also, the low cost of generics is the second major cause of the decline of the market. Generic versions of Ed drugs can be obtained at a minimal price. Hence, the availability of generics in the market will act as a challenge to the growth of the global erectile dysfunction (ED) market during the forecast period.

Buy Now Full Report

Key Erectile Dysfunction (ED) Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Erectile Dysfunction (ED) Drugs Market Customer Landscape

Segment Overview

The erectile dysfunction (ED) drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • End-user Outlook
    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy
  • Product Outlook
    • Oral drugs
    • Topical drugs
    • Others
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Argentina
      • Brazil
      • Australia

Erectile Dysfunction (ED) Drugs Market Scope

Report Coverage

Details

Page number

163

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 6.67%

Market Growth 2024-2028

USD 1.44 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.22

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Bayer AG, Cadila Pharmaceuticals Ltd., Cipla Ltd., Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Inc., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., and VIVUS LLC

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download the Sample PDF at your Fingertips

What are the Key Data Covered in this Erectile Dysfunction (ED) Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the erectile dysfunction (ED) drugs market between 2024 and 2028
  • Precise estimation of the erectile dysfunction (ED) drugs market size and its contribution of the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of erectile dysfunction (ED) drugs market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global erectile dysfunction (ED) drugs market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global erectile dysfunction (ed) drugs market 2018 - 2022 ($ million)
    • 4.2 End-user Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – End-user Segment 2018 - 2022 ($ million)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
    • 6.2 Comparison by End-user
      • Exhibit 32: Chart on Comparison by End-user
      • Exhibit 33: Data Table on Comparison by End-user
    • 6.3 Hospital pharmacy - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
    • 6.4 Retail pharmacy - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
    • 6.5 Online pharmacy - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by End-user
      • Exhibit 46: Market opportunity by End-user ($ million)
      • Exhibit 47: Data Table on Market opportunity by End-user ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 48: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 50: Chart on Comparison by Product
      • Exhibit 51: Data Table on Comparison by Product
    • 7.3 Oral drugs - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Oral drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 53: Data Table on Oral drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 54: Chart on Oral drugs - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Oral drugs - Year-over-year growth 2023-2028 (%)
    • 7.4 Topical drugs - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Topical drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Topical drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Topical drugs - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Topical drugs - Year-over-year growth 2023-2028 (%)
    • 7.5 Others - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Product
      • Exhibit 64: Market opportunity by Product ($ million)
      • Exhibit 65: Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Canada - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.9 Germany - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.10 China - Market size and forecast 2023-2028
      • Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.11 UK - Market size and forecast 2023-2028
      • Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 Bayer AG
              • Exhibit 115: Bayer AG - Overview
              • Exhibit 116: Bayer AG - Business segments
              • Exhibit 117: Bayer AG - Key news
              • Exhibit 118: Bayer AG - Key offerings
              • Exhibit 119: Bayer AG - Segment focus
            • 12.4 Cadila Pharmaceuticals Ltd.
              • Exhibit 120: Cadila Pharmaceuticals Ltd. - Overview
              • Exhibit 121: Cadila Pharmaceuticals Ltd. - Product / Service
              • Exhibit 122: Cadila Pharmaceuticals Ltd. - Key offerings
            • 12.5 Cipla Ltd.
              • Exhibit 123: Cipla Ltd. - Overview
              • Exhibit 124: Cipla Ltd. - Business segments
              • Exhibit 125: Cipla Ltd. - Key news
              • Exhibit 126: Cipla Ltd. - Key offerings
              • Exhibit 127: Cipla Ltd. - Segment focus
            • 12.6 Dr Reddys Laboratories Ltd.
              • Exhibit 128: Dr Reddys Laboratories Ltd. - Overview
              • Exhibit 129: Dr Reddys Laboratories Ltd. - Business segments
              • Exhibit 130: Dr Reddys Laboratories Ltd. - Key offerings
              • Exhibit 131: Dr Reddys Laboratories Ltd. - Segment focus
            • 12.7 Eli Lilly and Co.
              • Exhibit 132: Eli Lilly and Co. - Overview
              • Exhibit 133: Eli Lilly and Co. - Product / Service
              • Exhibit 134: Eli Lilly and Co. - Key news
              • Exhibit 135: Eli Lilly and Co. - Key offerings
            • 12.8 Endo International Plc
              • Exhibit 136: Endo International Plc - Overview
              • Exhibit 137: Endo International Plc - Business segments
              • Exhibit 138: Endo International Plc - Key news
              • Exhibit 139: Endo International Plc - Key offerings
              • Exhibit 140: Endo International Plc - Segment focus
            • 12.9 Futura Medical plc
              • Exhibit 141: Futura Medical plc - Overview
              • Exhibit 142: Futura Medical plc - Product / Service
              • Exhibit 143: Futura Medical plc - Key offerings
            • 12.10 Innovcare Lifesciences Pvt. Ltd.
              • Exhibit 144: Innovcare Lifesciences Pvt. Ltd. - Overview
              • Exhibit 145: Innovcare Lifesciences Pvt. Ltd. - Product / Service
              • Exhibit 146: Innovcare Lifesciences Pvt. Ltd. - Key offerings
            • 12.11 Lupin Ltd.
              • Exhibit 147: Lupin Ltd. - Overview
              • Exhibit 148: Lupin Ltd. - Product / Service
              • Exhibit 149: Lupin Ltd. - Key news
              • Exhibit 150: Lupin Ltd. - Key offerings
            • 12.12 Pfizer Inc.
              • Exhibit 151: Pfizer Inc. - Overview
              • Exhibit 152: Pfizer Inc. - Product / Service
              • Exhibit 153: Pfizer Inc. - Key news
              • Exhibit 154: Pfizer Inc. - Key offerings
            • 12.13 SK Inc.
              • Exhibit 155: SK Inc. - Overview
              • Exhibit 156: SK Inc. - Product / Service
              • Exhibit 157: SK Inc. - Key offerings
            • 12.14 Teva Pharmaceutical Industries Ltd.
              • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 160: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 162: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.15 TTK Healthcare Ltd.
              • Exhibit 163: TTK Healthcare Ltd. - Overview
              • Exhibit 164: TTK Healthcare Ltd. - Business segments
              • Exhibit 165: TTK Healthcare Ltd. - Key offerings
              • Exhibit 166: TTK Healthcare Ltd. - Segment focus
            • 12.16 Viatris Inc.
              • Exhibit 167: Viatris Inc. - Overview
              • Exhibit 168: Viatris Inc. - Business segments
              • Exhibit 169: Viatris Inc. - Key news
              • Exhibit 170: Viatris Inc. - Key offerings
              • Exhibit 171: Viatris Inc. - Segment focus
            • 12.17 VIVUS LLC
              • Exhibit 172: VIVUS LLC - Overview
              • Exhibit 173: VIVUS LLC - Product / Service
              • Exhibit 174: VIVUS LLC - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 175: Inclusions checklist
                • Exhibit 176: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 177: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 178: Research methodology
                • Exhibit 179: Validation techniques employed for market sizing
                • Exhibit 180: Information sources
              • 13.5 List of abbreviations
                • Exhibit 181: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              erectile dysfunction (ed) drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis